Quarterly ResultMay 7, 2026, 05:07 PM
Cytek Biosciences Q1 Net Loss Widens to $(18.9)M; Revenue Up 6.5%
AI Summary
Cytek Biosciences reported a significant increase in net loss for Q1 2026, reaching $(18.9) million, compared to $(11.4) million in Q1 2025. Despite this, total revenue grew by 6.5% to $44.1 million, driven by strong service revenue growth. The company also saw an increase in cash used in operating activities and a decrease in cash and cash equivalents.
Key Highlights
- Net loss widened to $(18.9) million in Q1 2026 from $(11.4) million in Q1 2025.
- Total revenue increased 6.5% to $44.1 million in Q1 2026 from $41.5 million in Q1 2025.
- Product revenue grew 2.4% to $28.8 million, while service revenue rose 15.1% to $15.4 million.
- Net loss per share was $(0.15) in Q1 2026, compared to $(0.09) in Q1 2025.
- Gross profit increased 5.4% to $21.3 million in Q1 2026.
- Cash and cash equivalents decreased to $65.7 million as of March 31, 2026, from $90.9 million at December 31, 2025.
- Net cash used in operating activities was $(2.7) million in Q1 2026, up from $(0.1) million in Q1 2025.
Price Impact
More from CTKB